Contract Pharma Staff11.10.20
ProteoNic, a provider of technology and services for efficient production of biologics, has licensed its premium 2G UNic technology for boosting therapeutic protein production to Gilead Sciences. Gilead gains non-exclusive commercial rights for application of ProteoNic's technology platform to the development of its proprietary products from mammalian cells. Financial details of the agreement were not disclosed.
ProteoNic's protein expression technology improves production levels across a range of mammalian host cells and selection systems. It is applicable to all relevant protein classes, including standard antibodies, bispecifics, recombinant polyclonals and complex multi-chain molecules, and enables the economically viable production of difficult to express proteins.
By increasing transcription and translation rates via a combination of novel genetic elements, the highest possible production levels are achieved without impacting product quality and cell line stability. 2G UNic technology can be readily combined with other protein expression-enhancing technologies to improve their performance and is functional in random and targeted integration.
"We are pleased that we can play a role in the production of Gilead's therapeutic proteins,” said Frank Pieper, chief executive officer, ProteoNic. “ProteoNic's clients consistently achieve strongly increased cell line productivity and reduced manufacturing cost in the production of their biologics. We will continue our work towards reaching the maximum production potential for our clients."
ProteoNic's protein expression technology improves production levels across a range of mammalian host cells and selection systems. It is applicable to all relevant protein classes, including standard antibodies, bispecifics, recombinant polyclonals and complex multi-chain molecules, and enables the economically viable production of difficult to express proteins.
By increasing transcription and translation rates via a combination of novel genetic elements, the highest possible production levels are achieved without impacting product quality and cell line stability. 2G UNic technology can be readily combined with other protein expression-enhancing technologies to improve their performance and is functional in random and targeted integration.
"We are pleased that we can play a role in the production of Gilead's therapeutic proteins,” said Frank Pieper, chief executive officer, ProteoNic. “ProteoNic's clients consistently achieve strongly increased cell line productivity and reduced manufacturing cost in the production of their biologics. We will continue our work towards reaching the maximum production potential for our clients."
